Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
- Thursday, September 21, 2023, 7:01
- Finance
- Add a comment
CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced…
About the Author
adminasapcorp has written 38959 stories on this site.